We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
-15.1%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$242M
AUM Growth
-$72.5M
Cap. Flow
-$97.2K
Cap. Flow %
-0.04%
Top 10 Hldgs %
92.28%
Holding
16
New
2
Increased
1
Reduced
3
Closed
–

Top Buys

Rank Stock Value
1
ARQT icon
Arcutis Biotherapeutics
ARQT
+$22.7M
2
BEAM icon
Beam Therapeutics
BEAM
+$6.58M
3
CDTX
Cidara Therapeutics
CDTX
+$1.1M

Top Sells

Rank Stock Value
1
GOSS icon
Gossamer Bio
GOSS
+$24.1M
2
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
+$6.3M
3
EPIX
ESSA Pharma
EPIX
+$101K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REPL icon
1
Replimune Group
REPL
$814M
$52.8M 21.86%
5,323,455
– –
MORF
2
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$43.6M 18.04%
2,969,582
– –
GOSS icon
3
Gossamer Bio
GOSS
$66.5M
$43.4M 17.96%
4,275,726
-1,843,619
-30% -$24.1M
ARQT icon
4
Arcutis Biotherapeutics
ARQT
$3.42B
$25.2M 10.42%
+844,680
New +$22.7M
TBIO
5
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$24.3M 10.06%
2,437,603
– –
IMUX icon
6
Immunic
IMUX
$182M
$8.3M 3.43%
137,149
– –
PRTK
7
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$8.19M 3.39%
2,600,410
– –
EPIX
8
DELISTED
ESSA Pharma
EPIX
$6.76M 2.8%
1,689,848
-20,000
-1% -$101K
BEAM icon
9
Beam Therapeutics
BEAM
$2.58B
$5.45M 2.26%
+302,821
New +$6.58M
CDTX
10
DELISTED
Cidara Therapeutics
CDTX
$4.98M 2.06%
100,408
+18,382
+22% +$1.1M
KYNB
11
Kyntra Bio
KYNB
$28.5M
$4.54M 1.88%
5,226
– –
TRVI icon
12
Trevi Therapeutics
TRVI
$2.49B
$4.16M 1.72%
1,263,408
– –
PRVL
13
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$3.33M 1.38%
272,807
-396,100
-59% -$6.3M
JNCE
14
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$2.52M 1.04%
529,965
– –
OBSV
15
DELISTED
ObsEva SA Ordinary Shares
OBSV
$2.41M 1%
999,364
– –
PVLA
16
Palvella Therapeutics
PVLA
$1.98B
$1.71M 0.71%
9,384
– –

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q1 2020 Portfolio in Review

As of Q1 2020, Omega Fund Management held 16 positions worth $242M, down 23% from $314M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Omega Fund Management's Q1 2020 filing shows 2 new, 1 increased and 3 reduced positions. Its largest new stake was Arcutis Biotherapeutics: 844,680 shares worth $25.2M. The largest sale was Gossamer Bio, an estimated $24.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Omega Fund Management's largest Q1 2020 buy was Arcutis Biotherapeutics: 844,680 shares worth $25.2M.
  • Omega Fund Management added most to Cidara Therapeutics in Q1 2020, an estimated $1.1M increase.
  • Omega Fund Management's biggest Q1 2020 reduction was Gossamer Bio, cutting an estimated $24.1M.
  • Omega Fund Management's ten largest holdings make up 92% of its $242M portfolio in Q1 2020.
  • Omega Fund Management opened 2 new positions and closed 0 in Q1 2020.
  • Omega Fund Management's portfolio value fell 23% quarter-over-quarter to $242M.

Based on Omega Fund Management's 13F filing for Q1 2020, filed 14 May 2020.